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MaOBJECTIVES The purpose of this studywas to investigate diffusemyocardial ﬁbrosis in patients with systolic heart failure
(SHF) and in patients with heart failure with preserved ejection fraction (HFpEF) and the association with diastolic
dysfunction of the left ventricle (LV).
BACKGROUND Increased diffuse myocardial ﬁbrosis may impair LV diastolic function. However, no study has veriﬁed
the association between the degree of diffuse myocardial ﬁbrosis and the severity of impaired diastolic function in SHF
and HFpEF.
METHODS Forty patients with SHF, 62 patients with HFpEF, and 22 patients without HF underwent cardiac magnetic
resonance (CMR), including T1 mapping and cine CMR on a 3-T system. Extracellular volume fraction (ECV), a measure of
diffuse myocardial ﬁbrosis, was quantiﬁed from T1 mapping. Systolic and diastolic functions of the LV were assessed by
cine CMR. The ECV values and LV functional indexes were compared among the 3 groups. Associations between ECV and
LV diastolic function were also investigated.
RESULTS Compared with patients without HF, signiﬁcantly higher ECV was found in patients with SHF (31.2%
[interquartile range (IQR): 29.0% to 34.1%] vs. 27.9% [IQR: 26.2% to 29.4%], p < 0.001) and HFpEF (28.9% [IQR:
27.8% to 31.3%] vs. 27.9% [IQR: 26.2% to 29.4%], p ¼ 0.006). Peak ﬁlling rate, a diastolic functional index assessed by
cine CMR, was signiﬁcantly decreased in patients with SHF (1.00 s1 [IQR: 0.79 to 1.49 s1] vs. 3.86 s1 [IQR: 3.34 to 4.48
s1], p < 0.001) and HFpEF (2.89 s1 [IQR: 2.13 to 3.50 s1] vs. 3.86 s1 [IQR: 3.34 to 4.48 s1], p < 0.001). Myocardial
ECV was signiﬁcantly correlated with peak ﬁlling rate in the HFpEF group (r ¼ 0.385, p ¼ 0.002), but no correlation
was found in the SHF and non-HF groups (r ¼ 0.030, p ¼ 0.856 and r ¼ 0.238, p ¼ 0.285, respectively).
CONCLUSIONS In patients with HF, only those with HFpEF show a signiﬁcant correlation between increased diffuse
myocardial ﬁbrosis and impaired diastolic function. Diffuse myocardial ﬁbrosis plays a unique role in the pathogenesis of
HFpEF. (J Am Coll Cardiol Img 2014;7:991–7) © 2014 by the American College of Cardiology Foundation.H eart failure (HF) is a clinically deﬁned syn-drome with a wide range of ejection frac-tion (EF) values of the left ventricle (LV).
Patients with HF can be categorized into those with
impaired ejection fraction (systolic heart failure
[SHF]) and those with preserved ejection fraction
(HFpEF). Accumulating evidence shows that SHF
and HFpEF are 2 distinct disease entities and havem the *Department of Medical Imaging, National Taiwan University
dicine, National Taiwan University Hospital, Taipei, Taiwan; and the zC
iversity College of Medicine, Taipei, Taiwan. This work was supported
ants NSC-102-2314-B-002-087-MY2 and NSC102-2314-B-002-071-MY3).
ationships relevant to the contents of this paper to disclose. Drs. Su and
nuscript received February 3, 2014; revised manuscript received April 9,different etiology, epidemiology, and response to
treatment (1–6). Patients with HFpEF were previously
assumed to have a better prognosis than patients
with depressed systolic function. Recent data suggest
that mortality rates and rates of rehospitalization
are not signiﬁcantly different between the 2 groups.
Moreover, in contrast to the improvement in survival
in patients with SHF, mortality from HFpEF hasHospital, Taipei, Taiwan; yDepartment of Internal
enter for Optoelectronic Medicine, National Taiwan
in part by the National Science Council, Taiwan
All authors have reported that they have no
Lin contributed equally to this work.
2014, accepted April 22, 2014.
ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CMR = cardiac magnetic
resonance
ECG = electrocardiography
ECV = extracellular volume
fraction
EDV = end-diastolic volume
EF = ejection fraction
ESV = end-systolic volume
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
IQR = interquartile range
LV = left ventricle
MOLLI = modiﬁed Look-Locker
inversion recovery
MVR = mass-to-volume ratio
PER = peak ejection rate
PFR = peak ﬁlling rate
SHF = systolic heart failur
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992remained the same (2). Further information
regarding the changes in cardiac structure
and function in patients with HFpEF is
needed to understand the pathophysiology
of the disease and to gain insight for a poten-
tial therapeutic approach.
Diagnosis of HFpEF requires relatively
preserved systolic function and the presence
of diastolic dysfunction in patients with HF.
Various clinical and experimental studies
have shown the signiﬁcance of diffuse
myocardial ﬁbrosis as a cause of diastolic
dysfunction (7–9). Thus far, it remains un-
clear whether the degree of myocardial
ﬁbrosis is associated with the severity of
impaired diastolic function in patients with
HFpEF. Furthermore, impaired diastolic
function is not unique to patients with
HFpEF; it also occurs in patients with SHF.
The degree of diffuse ﬁbrosis and its rela-
tionship with ventricular function in patients
with SHF have not yet been reported.
Cardiac magnetic resonance (CMR) is a
promising tool to evaluate the structure and function
of the LV. Recent studies have shown that T1 mapping
of CMR is feasible to quantify the degree of diffuse
eSEE PAGE 998myocardial ﬁbrosis bymeasuring extracellular volume
fraction (ECV) of the myocardium (10–12). In this
study, we used the T1 mapping technique to quantify
diffuse myocardial ﬁbrosis in 3 groups of subjects,
including patients with SHF, patients with HFpEF, and
patients without HF. Our goal was to test the hypoth-
esis that the degree of diffuse myocardial ﬁbrosis is
associated with the severity of diastolic dysfunction in
patients with HFpEF. We further hypothesized that
the roles of diffuse myocardial ﬁbrosis in the patho-
physiology of diastolic dysfunction differ between
SHF and HFpEF.
METHODS
STUDY POPULATION. The study was approved by the
institutional review board of our hospital. All study
participants provided written informed consent. A
total of 106 patients who had a clinical history of HF
and met the following conditions were enrolled in the
HF group: symptoms of HF of New York Heart Asso-
ciation functional class II to III or a history of symp-
toms/signs of HF using the Framingham criteria (13)
and persistence of symptoms and signs of HF for
more than 3 months. In the HF group, 66 patients
with an EF >45% and LV diastolic dysfunctiondocumented by tissue Doppler echocardiography,
deﬁned as the mean of septal and lateral mitral
annular early diastolic velocity <8 cm/s (14), were
assigned to the HFpEF group, and 40 patients with an
EF <45% were deﬁned assigned to the SHF group.
Twenty-two patients who did not present a medical
history or current manifestations of symptoms and
signs of HF were recruited for the non-HF group.
Subjects were excluded from the study if they had
known signiﬁcant valvular heart diseases indicated
for percutaneous or surgical intervention, chronic
atrial ﬁbrillation, chronic pulmonary disease, active
myocardial ischemia deﬁned by a positive stress test
or unrevascularized signiﬁcant (70%) stenosis in
coronary arteries by angiography, or an estimated
glomerular ﬁltration rate <30 ml/min/1.73 m2.
IMAGING ACQUISITION. CMR was performed on a
3-T CMR system (Trio; Siemens, Erlangen, Germany)
with an 8-channel cardiovascular phased array torso
coil. Myocardial T1 mapping was performed with an
electrocardiography (ECG)-triggered modiﬁed Look-
Locker inversion recovery (MOLLI) sequence before
and 10 min after 0.15 mmol/kg intravenous adminis-
tration of the gadolinium-based contrast agent
(Omniscan, GE Healthcare Inc., Princeton, New Jer-
sey). The MOLLI protocol used 2 Look-Locker cycles
to acquire 7 images over 11 heartbeats, and the scan-
ning parameters were as follows: TR/TE, 1.9 ms/1.0
ms; ﬂip angle, 35; minimum inversion time, 110 ms;
inversion time increment, 80 ms; matrix size, 256 
192; slice thickness, 6 mm; spatial resolution, 1.28
mm; Generalized Autocalibrating Partially Parallel
Acquisition acceleration factor, 2; number of in-
versions, 2; images acquired after ﬁrst inversion, 5;
pause, 4 heartbeats; and images acquired after sec-
ond inversion, 2. Five evenly spaced short-axis slices
were acquired sequentially from the LV base to apex.
After post-contrast T1 acquisition, LGE images were
acquired by using an ECG-triggered phase-sensitive
inversion recovery prepared segmented fast gradient
echo pulse sequence (15) at the same short-axis slices
as those in the myocardial T1 mapping to identify
the focal ﬁbrosis or scarring.
Cine CMR was performed using a segmented
balanced steady-state gradient echo pulse sequence
with a retrospective ECG R-wave trigger. The scanning
parameters were as follows: TR/TE, 3.0 ms/1.5 ms; ﬂip
angle, 46; matrix size, 256  208; and spatial resolu-
tion, 1.21 mm. Multiple short-axis slices were pre-
scribed from the mitral oriﬁce to LV apex with slice
thickness of 8 mm and gap of 2 mm. The true temporal
resolution was 63 ms, and 30 cardiac phases were
reconstructed retrospectively for each slice level.
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993IMAGE ANALYSIS. Quantitative analysis of myocar-
dial ECV was performed on T1 maps. The regions of
interest in the blood and the myocardium of the LV
were drawn in the central area of the LV cavity and the
septal myocardium on T1 maps for each slice, respec-
tively. If the septal myocardium showed regional
hyperenhancement on the LGE images, the regions of
interest of the myocardium was redrawn in other
unenhanced myocardial regions. The averaged T1
values of the segmented regions of interest were then
computed. After subtracting the pre-contrast values
from the post-contrast values, the changes in the
relaxation rate (1/T1) in the blood and the myocardium
were obtained. Myocardial ECV values were calcu-
lated by using the ratio of the change in relaxation rate
in the myocardium to that in the blood and multiplied
by (1  hematocrit). We averaged each myocardial
ECV value over 5 short-axis slices for each subject (16).
For LV function and mass analysis, endocardial
and epicardial contours of the LV were determined at
each slice level on cine CMR and the area enclosed by
each contour was computed (17). LV volumes for each
time point were then determined using the Simpson
rule to obtain the volume-time curve of the LV. End-
diastolic volume (EDV) and end-systolic volume (ESV)
of the LV were assessed from the volume-time curve
for the maximal and minimal values and were used to
compute EF. To obtain the rate of change in LV vol-
ume (dV/dt), LV volumes at each cardiac phase were
ﬁrst normalized by EDV to eliminate “pseudonormal
ﬁlling” of the LV (18). We calculated the differential of
the volume change (dV/dt) and performed interpola-
tion with a cubic b-spline function with an interval of
1 ms. From the interpolated curve of dV/dt, systolic
and diastolic functional indexes were determined at
the minimal and maximal values as peak ejection rate
(PER) and peak ﬁlling rate (PFR), respectively. LV
mass was computed as the difference between LV
epicardial volume at end-diastole and EDV multiplied
by the density of the myocardium (1.05 g/ml). LV
geometric remodeling was determined from the
mass-to-volume ratio (MVR) by calculating the ratio
of LV mass with respect to EDV. LV volumes and mass
indexed to body surface area were also measured
from EDV, ESV, and LV mass divided by body
surface area. Image analysis was performed using
software developed in-house provided by MATLAB
7.9 (MathWorks, Inc., Natick, Massachusetts).
STATISTICAL ANALYSIS. Because the Shapiro-Wilk
test showed that most of the variables were not
normally distributed, all statistical analyses were
performed by nonparametric methods. Continuous
variables were expressed as medians and inter-
quartile ranges (IQRs), and categorical variableswere expressed as percentages. Categorical varia-
bles, including demographics, etiology of HF, and
medication use, were compared among different
groups of patients by using chi-square tests. Contin-
uous variables, including clinical characteristics,
myocardial ECV, and LV functional indexes and mass,
were tested by the nonparametric Kruskal-Wallis test,
and the Mann-Whitney U test was used for post-hoc
analysis for comparison of the medians between
different groups. The potential association between
myocardial ECV and each functional index was tested
by the Spearman rank correlation test. To test whether
the association between ECV and each functional in-
dex was signiﬁcantly different among the 3 groups,
the correlation coefﬁcient was transformed by the
formula given by Kullback (19) and the signiﬁcance
and post-hoc analyses were performed by chi-square
tests. A value of p < 0.05 was considered signiﬁcant.
Statistical analyses were performed using SPSS soft-
ware package version 19 (SPSS Inc., Chicago, Illinois).
RESULTS
All subjects successfully underwent CMR except for
4 patients who had severe arrhythmia causing failure
of ECG synchronization during the study session;
these 4 patients were excluded from the image anal-
ysis. Consequently, 40 patients with SHF, 62 patients
with HFpEF, and 22 patients without HF were enrolled
in the study. The demographics of the study popula-
tion are summarized in Table 1. There was no signiﬁ-
cant difference in age among groups, but there were
more male patients in the SHF group compared with
the HFpEF group (80% male vs. 52% male, p ¼ 0.001)
and the non-HF group (80% male vs. 32% male,
p < 0.001). In the HF group, patients with SHF had a
higher rate of prior myocardial infarction (40% vs.
12%, p < 0.001) than patients with HFpEF, whereas
patients with HFpEF had a higher rate of hypertension
than patients with SHF (75% vs. 39%, p < 0.001). There
was no signiﬁcant difference between patients with
HFpEF and patients without HF in comorbidities
except for a greater incidence of coronary artery
disease (CAD) in patients with HFpEF (52% vs. 18%,
p < 0.001).
MYOCARDIAL ECV AND T1 TIME. Group comparisons
of myocardial ECV and T1 time are listed in Table 2.
The myocardial ECV in patients with SHF was
signiﬁcantly higher than that in patients with HFpEF
(31.2% [IQR: 29.0% to 34.1%] vs. 28.9% [IQR: 27.8%
to 31.3%], p ¼ 0.001) and patients without HF
(31.2% [IQR: 29.0% to 34.1%] vs. 27.9% [IQR: 26.2% to
29.4%], p < 0.001). Patients with HFpEF also had
signiﬁcantly higher myocardial ECV than patients
TABLE 2 Left Ventri
ECV, % 31.2 (2
Pre-T1, ms 1,209 (1
Post-T1, ms 545 (5
EDV, ml 174 (1
ESV, ml 116 (9
EDV index,
ml/m2
106 (8
ESV index,
ml/m2
76 (5
EF, % 33 (2
PER, s1 1.53 (
PFR, s1 1.00 (0
LVM, g 153 (1
LVM index,
g/m2
91 (7
MVR 0.86 (0
Values are median (interqu
the non-HF group.
ECV ¼ extracellular volu
volume; LVM ¼ left ventric
rate; post-T1 ¼ post-contr
TABLE 1 Basic Demographics of the Studied Subjects
SHF
(n ¼ 40)
HFpEF
(n ¼ 62)
Non-HF
(n ¼ 22)
Age, yrs 63 (57–72) 69 (60–72) 63 (59–75)
Male 80*† 52 32
Body surface area, m2 1.73 (1.62–1.87) 1.71 (1.62–1.82) 1.65 (1.56–1.79)
Risk factors
Hypertension 39*† 75 82
Diabetes mellitus 23 25 18
Dyslipidemia 46 48 59
Chronic kidney disease 10 5 5
Stroke 3 2 5
Myocardial infarction 40*† 12 0
Peripheral arterial occlusive disease 3 3 5
Etiologies for HF
Coronary artery disease 46† 52† 18
Dilated cardiomyopathy 15 6 0
Medications
Aspirin 40† 31† 14
Clopidogrel 28 18 9
Angiotensin-converting enzyme
inhibitor
15 3 5
Angiotensin receptor blocker 44 55 41
Values are median (interquartile range) or %. *p < 0.05 compared with the HFpEF group. †p < 0.05 compared
with the non-HF group.
HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection fraction; SHF ¼ systolic heart failure.
Su et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 0 , 2 0 1 4
Diffuse Myocardial Fibrosis in HFpEF O C T O B E R 2 0 1 4 : 9 9 1 – 7
994without HF (28.9% [IQR: 27.8% to 31.3%] vs. 27.9%
[IQR: 26.2% to 29.4%], p ¼ 0.006). For pre-contrast
myocardial T1 time, no signiﬁcant difference was
found among the groups (Table 2). Post-contrast
myocardial T1 time in the SHF group wascular Function and Mass for Patients With and Without HF
SHF
(n ¼ 40)
HFpEF
(n ¼ 62)
Non-HF
(n ¼ 22)
9.0 to 34.1)*† 28.9 (27.8 to 31.3)† 27.9 (26.2 to 29.4)
,153 to 1,251) 1,201 (1,159 to 1,238) 1,185 (1,170 to 1,214)
29 to 612)*† 613 (568 to 655)† 649 (615 to 677)
44 to 226)*† 91 (72 to 116) 81 (69 to 101)
5 to 154)*† 22 (14 to 34) 16 (12 to 25)
0 to 129)*† 53 (43 to 66) 48 (43 to 60)
2 to 92)*† 12 (8 to 12) 9 (7 to 14)
6 to 40)*† 78 (64 to 81) 80 (74 to 84)
1.80 to 1.18)*† 3.45 (4.00 to 2.76) 3.56 (3.97 to 3.17)
.79 to 1.49)*† 2.89 (2.13 to 3.50)† 3.86 (3.34 to 4.48)
28 to 183)*† 121 (95 to 150)† 88 (74 to 102)
2 to 102)*† 68 (57 to 84) 54 (49 to 59)
.76 to 1.02)*† 1.27 (1.03 to 1.51)† 1.12 (0.95 to 1.33)
artile range). *p < 0.05 compared with the HFpEF group. †p < 0.05 compared with
me fraction; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-systolic
ular mass; MVR ¼ mass-to-volume ratio; PER ¼ peak ejection rate; PFR ¼ peak ﬁlling
ast T1 time; pre-T1 ¼ pre-contrast T1 time; other abbreviations as in Table 1.signiﬁcantly shorter than that in the HFpEF group (545
ms [IQR: 529 to 612 ms] vs. 613 ms [IQR: 568 to 655 ms],
p ¼ 0.002) and non-HF group (545 ms [IQR: 529 to
612 ms] vs. 649 ms [IQR: 615 to 677 ms], p < 0.001).
Patients with HFpEF also had signiﬁcantly shorter
post-contrast myocardial T1 time than patients
without HF (613 ms [IQR: 568 to 655 ms] vs. 649 ms
[IQR: 615 to 677 ms], p ¼ 0.016). To investigate
whether ischemic and nonischemic etiologies had
different effects on myocardial ECV and T1 time, we
categorized the SHF and HFpEF groups into 2 sub-
groups separately: patients with CAD and patients
without CAD. There was no signiﬁcant difference in
myocardial ECV between patients with and without
CAD for SHF (31.8% [IQR: 29.5% to 35.3%] vs. 31.2%
[IQR: 28.2% to 34.1%], p ¼ 0.352) and HFpEF (29.9%
[IQR: 28.1% to 31.5%] vs. 28.7% [IQR: 27.4% to
31.4%], p ¼ 0.117). Similarly, pre-contrast and post-
contrast myocardial T1 time showed no signiﬁcant
differences between patients with and without CAD
for both SHF and HFpEF groups.
FUNCTIONAL INDEXES OF THE LV. LV function and
mass quantiﬁed by cine CMR are summarized in
Table 2. LV functional indexes, including EDV, ESV,
EF, PFR, PER, and LV mass, were all signiﬁcantly
different in the SHF group as compared with the
HFpEF and non-HF groups. Comparing the HFpEF
with non-HF group, only PFR was signiﬁcantly
lower (2.89 s1 [IQR: 2.13 to 3.50 s1] vs. 3.86 s1
[IQR: 3.34 to 4.48 s1], p < 0.001) in the HFpEF
group. Despite a signiﬁcantly higher LV mass in the
HF group, MVR was signiﬁcantly smaller in the SHF
group as compared with the non-HF group (0.86
[IQR: 0.76 to 1.02] vs. 1.12 [IQR: 0.95 to 1.33], p ¼
0.012), whereas MVR was signiﬁcantly larger in the
HFpEF group as compared with the non-HF group
(1.27 [IQR: 1.03 to 1.51] vs. 1.12 [IQR: 0.95 to 1.33],
p ¼ 0.023).
CORRELATION BETWEEN MYOCARDIAL ECV AND
LV FUNCTION. To further investigate the correlation
between diffuse myocardial ﬁbrosis and LV function,
we performed correlation analysis between myocar-
dial ECV and each LV functional index for each group.
In the HFpEF group, myocardial ECV was signiﬁcantly
correlated with EDV (r ¼ 0.320, p ¼ 0.011), ESV (r ¼
0.474, p < 0.001), EF (r ¼ 0.539, p < 0.001), PER (r ¼
0.529, p < 0.001), PFR (r ¼ 0.385, p ¼ 0.002), and
LV mass (r ¼ 0.369, p ¼ 0.003) (Figure 1). There was no
signiﬁcant correlation between myocardial ECV
and LV functional indexes in the SHF group (EDV: r ¼
0.059, p ¼ 0.717; ESV: r ¼ 0.080, p ¼ 0.622; EF:
r ¼ 0.107, p ¼ 0.513; PER: r ¼ 0.062, p ¼ 0.703;
PFR: r ¼ 0.030, p ¼ 0.856; LV mass: r ¼ 0.096, p ¼
0.557) and non-HF group (EDV: r ¼ 0.045, p ¼ 0.842;
100
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FIGURE 1 Correlation Between Myocardial ECV and Left Ventricular Functional Index
Correlations between myocardial extracellular volume fraction (ECV) with ejection fraction (EF), peak ejection rate (PER), and peak ﬁlling rate
(PFR) in patients with heart failure with preserved EF.
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995ESV: r ¼ 0.015, p ¼ 0.948; EF: r ¼ 0.180, p ¼ 0.422;
PER: r ¼ 0.233, p ¼ 0.296; PFR: r ¼ 0.238, p ¼ 0.285;
LV mass: r ¼0.012, p ¼ 0.956). The differences in the
correlation coefﬁcients were signiﬁcant among the
3 groups (ECV-ESV, p ¼ 0.022; ECV-EF, p ¼ 0.008;
ECV-PER, p < 0.001; and ECV-PFR, p ¼ 0.025). Post-
hoc tests also showed that these correlations were
signiﬁcantly different between the HFpEF group and
the other 2 groups (data not shown).
DISCUSSION
In this study, we used myocardial ECV to quantify
diffuse myocardial ﬁbrosis in patients with HF. As
compared with patients without HF, myocardial ECV
was increased in patients with HF. In patients with
HF, ECV in SHF was higher than that in HFpEF,
indicating that patients with SHF have a greater
degree of diffuse myocardial ﬁbrosis than patients
with HFpEF. For the correlations between diffuse
myocardial ﬁbrosis and LV functional indexes, we
found that among patients with HF, only patients
with HFpEF had a signiﬁcant correlation between
ECV and diastolic function. Furthermore, myocardial
ECV was signiﬁcantly associated with apparently
normal systolic functional indexes, such as EF and
PER. These ﬁndings imply that diffuse myocardial
ﬁbrosis plays a unique role in patients with HFpEF,
affecting both systolic and diastolic functions.
Myocardial ﬁbrosis is deﬁned as a signiﬁcant in-
crease in the collagen content in the myocardium,
which has been considered the endpoint pathological
process of the myocardium, leading to impaired ven-
tricular function. Increased diffusemyocardial ﬁbrosis
has been reported to be a major determinant of altered
diastolic ﬁlling and systolic pumping function of theLV (20). Onceﬁbrosis develops, it increasesmyocardial
stiffness and eventually deteriorates diastolic and
systolic functions. The pathophysiology of accumu-
lating collagen contents is diverse, depending on
various cardiomyopathies (21). In general, 2 different
types ofmyocardialﬁbrosis can be characterized on the
basis of pathological results; 1 type shows increased
collagen synthesis within the interstitium, and the
other type shows replacement of myocytes with scar-
ring (21). Diffuse myocardial ﬁbrosis resulting from
abnormal collagen accumulation within the inter-
stitium is histologically different from the replacement
ﬁbrosis or scars resulting from previous myocyte
death. Martos et al. (22) used biomarkers of serological
ﬁbrosis to investigate the myocardial collagen con-
tents in patients with HFpEF and found elevated levels
of serum ﬁbrotic biomarkers, indicating increased
collagen synthesis in patients with HFpEF. Borbely
et al. (23) used endomyocardial biopsy to determine
the extent of myocardial ﬁbrosis in patients with
HFpEF and reported a signiﬁcantly higher collagen
volume fraction in patients with HFpEF compared
with patientswithoutHF. In contrast to replacement or
scarring ﬁbrosis, which is often found in the infarcted
myocardium, the predominant type of ﬁbrosis in pa-
tients with HFpEF is interstitial ﬁbrosis with a diffuse
distribution surrounding the myocytes. Using the T1
mapping technique to quantify diffuse myocardial
ﬁbrosis in patients with HF, we found that diffuse
myocardialﬁbrosis is indeed increased in both patients
with SHF and patients with HFpEF. Interestingly, our
results showed no signiﬁcant association between ECV
and ventricular functional indexes in patients with
SHF. For patients with SHF, the prevalence of previous
myocardial infarction is higher than that in HFpEF
(40% vs. 12%). Infarcted myocardium is the result of
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996myocyte death, followed by replacement with scarring
ﬁbrosis. This type of ﬁbrosis might affect LV function
independently of diffuse myocardial ﬁbrosis. There-
fore, in patients with SHF, replacement ﬁbrosis or scar
may contribute more to ventricular dysfunction than
diffuse myocardial ﬁbrosis.
Hypertension is a major risk factor for developing
HF (24). Enhanced collagen synthesis and increased
collagen volume fraction in the hypertensive
myocardium have been reported in postmortem au-
topsies (20,25) and endomyocardial biopsy specimens
of human hearts (26,27). Patients with HFpEF have a
higher prevalence rate of hypertension as compared
with those with SHF (2). Because diffuse myocardial
ﬁbrosis may be increased in patients with hyperten-
sion, we enrolled subjects without HF but with a
prevalence of hypertension, similar to the HFpEF
group, as controls to control the effect of hyperten-
sion on diffuse myocardial ﬁbrosis. In fact, the effect
of hypertension on diffuse myocardial ﬁbrosis was
examined by Querejeta et al. (28) by using serum
ﬁbrosis markers and endomyocardial biopsy speci-
mens. They found that hypertensive patients with HF
have signiﬁcantly more diffuse interstitial ﬁbrotic
depositions than those without HF. By comparing the
HFpEF and non-HF groups, which had a comparable
prevalence of hypertension, this study further sup-
ports that diffuse myocardial ﬁbrosis is indeed
increased in patients with HF besides the presence of
hypertension.
Myocardial T1 time is a measure of the longitudinal
relaxation rate of magnetization, and it can be per-
formed before and after gadolinium-based contrast
administration. Several studies have used post-
contrast myocardial T1 time to quantify diffuse
myocardial ﬁbrosis in patients with various cardio-
myopathies (21,29,30). However, post-contrast myo-
cardial T1 time is affected by several factors, such as
magnetic ﬁeld strength, the timing of post-contrast
MOLLI acquisition, the type of MOLLI scheme, the
amount of contrast injected, and the renal function of
patients (31). In contrast, myocardial ECV is measured
by normalization of myocardial T1 time with blood T1
time, which is theoretically less affected by these
factors. Lee et al. (32) compared different post-
contrast scanning times and different types of
MOLLI schemes to estimate myocardial ECV and T1
time at 1.5-T and 3.0-T. They reported that myocar-
dial ECV appears to be more stable and should not be
affected by these variables. Recent studies have
proved that increased ECV is associated with the
severity of diffuse myocardial ﬁbrosis in histology
(10,12). Therefore, myocardial ECV is more favorable
than post-contrast myocardial T1 time to estimateextracellular matrix expansion such as diffuse myo-
cardial ﬁbrosis.
SHF and HFpEF are fundamentally different dis-
ease entities and have different manifestations of LV
geometric remodeling. The disparate patterns of LV
remodeling have been widely recognized; patients
with SHF present with eccentric LV remodeling with
low MVR, and patients with HFpEF manifest
concentric LV remodeling with high MVR (33,34).
Sanderson (35) emphasized the importance of the
remodeling process in determining whether a patient
has SHF or HFpEF (35). Compared with patients
without HF, we found signiﬁcantly higher ventricular
volume and larger LV mass in patients with SHF,
leading to signiﬁcantly lower MVR. In contrast, pa-
tients with HFpEF had normal ventricular volume
and larger LV mass, resulting in signiﬁcantly higher
MVR. This geometric remodeling is consistent with
previous results measured from echocardiography
(34), suggesting that CMR is feasible to discriminate
the changes in structure and function of the LV for
patients with HF.
STUDY LIMITATIONS. First, this study has no histo-
logical evidence to validate the results regarding the
changes in myocardial ECV because all subjects had
no indication for endomyocardial biopsy. Second, the
values of myocardial ECV were mainly measured from
the LV septum, but some were measured from non-
septal areas if there were hyperenhanced scars in the
LV septum. Although a previous study showed that
there is no regional difference of ECV in healthy
subjects (36), there is still a possibility of bias. Third,
because the temporal resolution of cine CMR is infe-
rior to echocardiography, the LV function assessed by
CMR might not be accurate. One study has already
shown that CMR-derived indexes such as PFR are a
sensitive indicator to detect LV diastolic dysfunction
(37). Therefore, we believe that cine CMR is a valid
method to assess LV diastolic function.
CONCLUSIONS
In this study, we showed that diffuse myocardial
ﬁbrosis is increased in patients with HF. The
increased myocardial ﬁbrosis is associated with
ventricular functional indexes in patients with
HFpEF. For patients with SHF, the diffuse myocardial
ﬁbrosis is more severe than that in patients with
HFpEF, but the degree of diffuse myocardial ﬁbrosis
seems unrelated to the impairment of ventricular
function. These data support that diffuse myocardial
ﬁbrosis is a key factor in the pathophysiology of
HFpEF and may play a unique role leading to diastolic
dysfunction in patients with HFpEF.
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